Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 253-057-0 | CAS number: 36483-57-5
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2004
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP and appropriate guidelines
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 004
- Report date:
- 2004
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
- Principles of method if other than guideline:
- not relevant
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- 2,2-dimethylpropan-1-ol, tribromo derivative
- EC Number:
- 253-057-0
- EC Name:
- 2,2-dimethylpropan-1-ol, tribromo derivative
- Cas Number:
- 36483-57-5
- Molecular formula:
- C5H9Br3O
- IUPAC Name:
- 3-bromo-2,2-bis(bromomethyl)propan-1-ol
- Details on test material:
- Identification: FR-513
Mol. formula: C5H9Br3O
Mol. Weight: 324.92
CAS #: 36483-57-5
Description: White flakes
Batch: 039084 (taken from label)
Composition: Tribromoneopentyl alchohol 97%, Dibromoneopentyl glycol < 0.1%
Storage: At room temperature in the dark
Stability under storage conditions: Stable
Constituent 1
Method
- Target gene:
- not relevant
Species / strain
- Species / strain / cell type:
- lymphocytes: Peripheral human lymphocytes
- Metabolic activation:
- with and without
- Metabolic activation system:
- Aroclor-1254 induced rat liver S9-mix
- Test concentrations with justification for top dose:
- Range finder test: control: (DMSO), 33, 100, 333, 1000, 3250µg/ml (-S9-mix) (3hr, 24 hr, 48 hr exposure; 24hr, 24hr,48 hr fixation) ; control (DMSO), 33, 100, 333, 1000, 3250µg/ml (+S9-mix) (3hr exposure; 24hr fixation)
Main test 1: control (DMSO), 100, 333, 666, 1000, 1250, 1500, 2000 µg/ml, MMC-C (0.5 µg/ml) (-S9-mix)(3hr exposure, 24 hr fixation); control (DMSO), 100, 333, 666, 1000, 1250, 1500, 2000 µg/ml, CP (15 µg/ml) (+S9-mix)(3hr exposure, 24 hr fixation)
Main test 1A: control (DMSO), 100, 333, 666, 1000, 1050, 1100, 1150, 1200 µg/ml, MMC-C (0.5 µg/ml) (-S9-mix)(3hr exposure, 24 hr fixation); control (DMSO), 100, 333, 666, 1000, 1050, 1100, 1150, 1200 µg/ml, CP (15 µg/ml) (+S9-mix)(3hr exposure, 24 hr fixation)
Main test 1B: control (DMSO), 333, 1000, 1010, 1020, 1030, 1040, 1050 µg/ml, CP (15 µg/ml) (+S9-mix)(3hr exposure, 24 hr fixation)
Main test 1C: control (DMSO), 333, 666, 1000 µg/ml, MMC-C (0.5 µg/ml) (-S9-mix)(3hr exposure, 24 hr fixation); control (DMSO), 333, 666, 1000, 1020, 1050, 1100, 1200 µg/ml, CP (15 µg/ml) (+S9-mix)(3hr exposure, 24 hr fixation)
Main test 1D: control (DMSO), 100, 300, 600, 800, 1000, 1020, 1030, 1050, 1100 µg/ml, CP (15 µg/ml) (+S9-mix)(3hr exposure, 24 hr fixation)
Main test 2: control (DMSO), 17, 66, 100, 126, 150, 200 µg/ml, MMC-C (0.2 µg/ml) (-S9-mix)(24 hr exposure, 24 hr fixation); control (DMSO), 1, 3, 10,17, 66, 100 µg/ml, MMC-C (0.1 µg/ml) (-S9-mix)(48 hr exposure, 48 hr fixation); control (DMSO), 100, 167, 666, 1000, 1250, 1500, 2000 µg/ml, CP (15 µg/ml) (+S9-mix)(3 hr exposure, 3 hr fixation)
Main test 2: control (DMSO), 17, 66, 100, 126, 150, 200 µg/ml, MMC-C (0.2 µg/ml) (-S9-mix)(24 hr exposure, 24 hr fixation); control (DMSO), 1, 3, 10,17, 66, 100 µg/ml, MMC-C (0.1 µg/ml) (-S9-mix)(48 hr exposure, 48 hr fixation)
Main test 2A: see in materials and methods* - Vehicle / solvent:
- DMSO
Controls
- Untreated negative controls:
- yes
- Remarks:
- DMSO
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- Positive controls:
- yes
- Remarks:
- Mytomycin (MMC-C) (-S9-mix)
- Positive control substance:
- cyclophosphamide
- Remarks:
- Migrated to IUCLID6: (CP) + (S9-mix)
- Details on test system and experimental conditions:
- see attached document on test system and conditions
- Evaluation criteria:
- see attached document on data evaluation and statistical procedures
- Statistics:
- see attached document on data evaluation and statistical procedures
Results and discussion
Test resultsopen allclose all
- Species / strain:
- lymphocytes: Peripheral human lymphocytes
- Metabolic activation:
- with and without
- Genotoxicity:
- not determined
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- cell lysis at 3250µg/ml
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- lymphocytes: Peripheral human lymphocytes
- Metabolic activation:
- without
- Genotoxicity:
- not determined
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- 1000µg/ml
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- lymphocytes: Peripheral human lymphocytes
- Metabolic activation:
- with
- Genotoxicity:
- not determined
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- 100µg/ml, 1020 µg/ml
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- lymphocytes: Peripheral human lymphocytes
- Metabolic activation:
- with
- Genotoxicity:
- not determined
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Species / strain:
- lymphocytes: Peripheral human lymphocytes
- Metabolic activation:
- with
- Genotoxicity:
- not determined
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- 1100 µg/ml
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- see attached document on results
- Remarks on result:
- other: other: range finding test
- Remarks:
- Migrated from field 'Test system'.
Any other information on results incl. tables
see attached document on tables
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information):
positive clastogenic in the presence and in the absence of metabolic activation
FR-513 was found to be clastogenic in the presence of metabolic activation and at the highest test substance concentration (1000 microgram/ml) in the absence of metabolic activation. FR-513 has the potential to disturb mitotic processes and cell cycle progression. - Executive summary:
Evaluation of the ability of FR-513 to induce chromosome aberrations in cultured peripheral human lymphocytes was conducted using appropriate guidelines such as OECD 473. The report describes the effect of FR-513 on the number of chromosome aberrations in cultures perpheral human lymphocytes in the presence and absence of a metabolic activation system. A range finder study was conducted which followed by several main tests.
It is concluded that the test was valid and under the experimental conditions FR-513 was found to be clastogenic in the presence of metabolic activation and at the highest test substance concentration (1000 microgram/ml) in the absence of metabolic activation. FR-513 has the potential to disturb mitotic processes and cell cycle progression.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
